HYTN Innovations Inc., a company at the forefront of developing, formulating, and manufacturing products with psychoactive and psychotropic compounds, including those from cannabis and psilocybin, proudly announces the successful completion of a Good Manufacturing Practices (“GMP”) audit by Australia’s Therapeutic Goods Administration (“TGA”) at their Kelowna facility. The positive outcome of the audit has set the stage for the subsequent issuance of formal GMP certification allowing the company to access international medical markets.
The successful GMP audit, in coordination with Australia’s Promethean Biopharma, confirms HYTN as one of the few companies in Canada qualified to package and label finished cannabis goods in accordance with GMP regulations for international medical markets; facilitating the supply of high-quality medical cannabis products to international clients and enabling collaboration with global firms.
The GMP audit conducted by the TGA was performed in accordance with the standards of the Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme (“PIC/S”). The successful audit is a key achievement for HYTN, demonstrating the robustness of the company’s infrastructure and the effectiveness of its processes. Once issued, GMP certification under the PIC/S framework allows HYTN to engage with international medical markets that recognize the PIC/S standard, through established reciprocal agreements. This milestone aligns with the growth of robust international cannabis markets which require GMP certification to effectively commercialize.
“We’re pleased to announce this important milestone,” said Elliot McKerr, Chief Executive Officer of HYTN. “Our capability in Canada to convert cannabis biomass into GMP-compliant finished products, combined with our strategic location near top cultivators, positions us well to capitalize on the growing global cannabis market and drive revenue growth. We look forward to serving the global demand for GMP cannabis goods and exploring new partnership possibilities through HYTN’s enhanced capabilities.”
While HYTN continues to prioritize domestic recreational products, such as its popular 10mg THC Sparkling Beverages and 100mg Nano Shot Citrus, obtaining a GMP license will expand the company’s commercial opportunities. Jason Broome, Chief Operating Officer of HYTN, emphasized the significance of this achievement, stating, “Moving towards GMP approval presented significant organizational challenges; however, having overcome them, we are now poised to enter the global cannabis market in new and exciting ways. This step also allows us to elevate our existing systems, bringing our current and future product offerings into compliance with GMP standards.”
About HYTN Innovations Inc.
HYTN formulates, manufactures, markets, and sells premium products containing psychoactive and psychotropic compounds, including cannabis-derived cannabinoids. HYTN’s mission is to become the top provider of these products in all federally regulated markets. To achieve this, the company focuses on identifying market opportunities and quickly bringing its innovative products to market through its elevated development platform.
